Antiangiogenic Therapy for Malignant Gliomas
Author Information
Author(s): Katsuyuki Shirai, Michael R. Siedow, Arnab Chakravarti
Primary Institution: The Ohio State University Comprehensive Cancer Center
Hypothesis
Can antiangiogenic therapy improve outcomes for patients with malignant gliomas?
Conclusion
Bevacizumab shows promise in improving progression-free survival for patients with recurrent malignant gliomas, but its impact on overall survival remains unclear.
Supporting Evidence
- Bevacizumab was approved by the FDA for recurrent glioblastoma based on promising response rates.
- Clinical trials showed that the addition of bevacizumab improved progression-free survival in glioblastoma patients.
- Bevacizumab has shown effectiveness in recurrent anaplastic gliomas as well.
Takeaway
Doctors are trying a new medicine called bevacizumab to help people with brain tumors feel better and live longer, but they are still figuring out how well it works.
Methodology
The study reviews clinical trials and outcomes of bevacizumab and other antiangiogenic therapies for malignant gliomas.
Potential Biases
Potential enrollment bias and reliance on historical control data.
Limitations
The studies reviewed have small sample sizes and may not be generalizable.
Participant Demographics
Patients with recurrent glioblastoma and anaplastic gliomas.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website